TOP BRD4 INHIBITION BY ABBV-744 IN CANCER RESEARCH STUDIES SECRETS

In Phase C, individuals will receive ABBV-744 and oral navitoclax. In Section D, contributors will receive ABBV-744 and ruxolitinib. Members will acquire treatment until sickness progression or even the contributors are unable to tolerate the study drugs.- "Our study exposed the vital part in the KLF16/MYC regulatory axis in modulating tumor growth